2025-12-31 - Analysis Report
Okay, here's a breakdown and analysis of Intuitive Surgical (ISRG) based on the provided data.

**1) Return Rate vs. S&P 500 (VOO)**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.
*   **Cumulative Return (ISRG):** 111.62%
*   **Cumulative Return (VOO):** 102.21%
*   **Divergence:**
    *   Current: 10.3
    *   Relative Divergence: 35.2

**Analysis:**

ISRG has outperformed the S&P 500 (VOO) in cumulative returns. The current divergence is 10.3 percentage points. The relative divergence of 35.2 indicates that the current outperformance is somewhat below the middle range of historical divergence between ISRG and VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2015-2017  | 68.0%  | 77.6% | 40.0%  | -0.1  | 43.6   |
| 2016-2018  | 64.0%  | 72.2% | 49.0%  | -0.0  | 57.2   |
| 2017-2019  | 54.0%  | 72.2% | 31.0%  | 0.2   | 70.6   |
| 2018-2020  | -6.0%  | 80.4% | -29.0% | 0.3   | 97.8   |
| 2019-2021  | 29.0%  | 80.4% | -18.0% | 0.6   | 128.8  |
| 2020-2022  | -23.0% | 80.4% | -22.0% | 1.2   | 95.1   |
| 2021-2023  | -17.0% | 77.5% | -18.0% | 1.7   | 120.9  |
| 2022-2024  | 36.0%  | 77.5% | 15.0%  | 1.7   | 187.1  |
| 2023-2025  | 74.0%  | 72.7% | 7.0%  | 0.8   | 205.3  |

**Analysis:**

*   **CAGR:** Wide range of CAGR values, from negative to strongly positive, reflecting volatility in the stock's performance. The most recent period (2023-2025) shows strong growth.
*   **MDD:** High Maximum Drawdown (MDD) values consistently above 70% indicate significant price declines at times.
*   **Alpha:** Alpha fluctuates significantly, often negative in recent periods. This suggests that ISRG's performance has not always exceeded expectations based on its risk.
*   **Beta:** Beta is generally low, and even negative in early periods, meaning that ISRG's price is not strongly correlated to the S&P 500 market index. However, the beta has increased over time, indicating a growing correlation with the market.
*   **Cap(B):** The market capitalization has grown considerably over the years, reflecting the company's expansion, but it has had some volatility.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 572.63
*   **Last Market Data:** Price: 572.63, Previous Close: 575.4, Change: -0.48
*   **5-day SMA:** 576.07
*   **20-day SMA:** 565.87
*   **60-day SMA:** 536.02

**Analysis:**

*   The current price is slightly below the previous close, indicating a small recent dip.
*   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This suggests a short-term uptrend. However, the current price is below the 5-day SMA, hinting at a possible reversal or consolidation.

**3) RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 60.11
*   **PPO:** 0.0062
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 1.3 (+) (Short-term Increase)
*   **Expected Return (%):** 24.5 (Expected excess return compared to S&P 500 if invested long-term).

**Analysis:**

*   The Market Risk Indicator is high, suggesting a favorable environment for investment.
*   The RSI of 60.11 is above 50 and trending upward, but not in overbought territory, indicating positive momentum but not extreme conditions.
*   The PPO is positive but relatively small, suggesting a minor degree of bullish momentum.
*   The hybrid signal suggests a strong buy recommendation (90% of cash to be deployed)
*   The recent increase in relative divergence further suggests a short-term upward trend.
*   A strong expected return (24.5%) offers a positive outlook for long-term investors.

**4) Recent News & Significant Events**

*   **Mirova US LLC Sold Shares:** Suggests some institutional selling pressure, which could be a minor concern.
*   **Golden Crossover:** This is a bullish technical signal, indicating a potential uptrend.
*   **High Margins, Discount:** Reports suggest the stock may be undervalued based on its strong profit margins.
*   **Buy Opportunity or Risk Ahead:** Mixed opinions regarding the stock's near-term potential.
*   **AI Surgical Systems:** The company is actively innovating in AI-driven surgical solutions, pointing to future growth potential.

**4-2) Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.06 (~Buy)
*   **Target Price:** Average: 599.60, High: 700.00, Low: 378.00

**Analysis:**

The analyst consensus is generally positive, with a buy rating and an average target price significantly above the current price.

**5) Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-10-22 | 1.98 | 2.51 B$       |
| 2025-07-23 | 1.84 | 2.44 B$       |
| 2025-04-23 | 1.95 | 2.25 B$       |
| 2024-10-18 | 1.59 | 2.04 B$       |
| 2025-10-22 | 1.59 | 2.04 B$       |

**Analysis:**

The table shows a clear trend of increasing EPS and revenue over the past few quarters, indicating strong financial performance.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $2.51B  | 66.36%        |
| 2025-06-30   | $2.44B  | 66.31%        |
| 2025-03-31   | $2.25B  | 64.69%        |
| 2024-12-31   | $2.41B  | 68.04%        |
| 2024-09-30   | $2.04B  | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE   |
|--------------|---------|-------|
| 2025-09-30   | $16.93B | 4.16% |
| 2025-06-30   | $17.85B | 3.69% |
| 2025-03-31   | $17.11B | 4.08% |
| 2024-12-31   | $16.43B | 4.17% |
| 2024-09-30   | $15.58B | 3.63% |

**Analysis:**

*   **Revenue and Profitability:** Revenue is generally increasing, and profit margins remain very high, indicating a strong and efficient business.
*   **Capital and Profitability:** Equity is stable, and Return on Equity (ROE) is consistent, showing a solid return on shareholder investment.

**7) Comprehensive Analysis (Summary)**

Intuitive Surgical (ISRG) presents a mixed but generally positive outlook:

*   **Strengths:**
    *   Strong historical outperformance compared to the S&P 500.
    *   Solid recent earnings growth.
    *   High profit margins and Return on Equity.
    *   Positive analyst consensus and target price.
    *   Bullish technical indicators (Golden Crossover).
    *   Innovative leadership in robotic surgery and AI applications.
    *   High Market Risk Indicator signals a favorable environment for investment.
*   **Weaknesses/Concerns:**
    *   High historical volatility and Maximum Drawdown.
    *   Recent institutional selling.
    *   A short-term price decrease and price below the 5-day SMA suggesting caution.
    *   Fluctuating Alpha suggests performance not always exceeding expectations based on risk.

**Overall Conclusion:**

ISRG appears to be a fundamentally strong company with a positive outlook. The recent dip in price could present a buying opportunity, especially considering the analyst consensus and the company's growth potential. However, investors should be aware of the stock's historical volatility and potential downside risks, particularly considering recent institutional selling.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.